Lucius Pharmaceuticals
International business
Lucius Pharmaceuticals

Science with a clear point of view.

Lucius Pharmaceuticals presents an evidence-aware platform for Aildenafil phosphate and research into ischemic stroke biology.

Explore AildenafilView evidence
Conceptual neurovascular branching and tissue-network illustration
PK / PD · 01
0.5 hSource peakPK/PD context

Source constraint, not dosing guidance

01 / Disease context

A local interruption changes the field downstream.

A conceptual sequence from flow to tissue stress. It explains a research question; it is not a clinical simulation.

Conceptual illustration from healthy flow through local interruption to downstream tissue stress
01 / Flow context
02 / Aildenafil phosphate

Aildenafil at a glance.

Aildenafil phosphate is the lead product story in the Lucius v1 scientific information platform, presented through source-mapped product information and preclinical research context.

Parameter context

Source-reported tablet strength; not individualized dosing guidance.

03 / Source-aware figures

Evidence should answer a question—not decorate a metric.

Three source-mapped views move from exposure, to timing, to the questions that connect the evidence.

FIG. 01Mixed · normalized illustrative

Exposure peaks at 0.5 h and falls below 5% of peak by 6 h.

Lieflat Basics F2 hairline-line structure. Solid points show source constraints. Continuous profiles are normalized illustrative reconstructions, not measured intermediate concentrations.
Normalized plasma and brain exposure illustration Peak at 0.5 hours and below 5 percent at 6 hours. Continuous hairlines are normalized illustrations.0 h0.5 h1 h2 h4 h6 h8 hnormalized peak = 100one dot = one illustrative sample0.5 h peak<5% @ 6 h1.24×brain AUC / plasma AUC
FIG. 02Observed events · temporal lineage

The source narrative spans 2, 6 and 24 h—without an efficacy scale.

Three lineages start at the MCAO model event and terminate at source-reported administration times; line length encodes time only.
Administration-event lineages after MCAO Three vertical lineages extend from the MCAO model event to source-reported administration at 2, 6 and 24 hours.hours after MCAO0 h2 h6 h12 h18 h24 hT+02source administrationmodel eventT+06source administrationT+24source administrationno effect-size encoding
FIG. 03Conceptual · source mapped

One source baseline branches into three distinct research questions.

Nine source-mapped records resolve into tissue stress, administration time and brain exposure; links do not encode causality or effect size.
Evidence-question ownership map Nine source-mapped records connect by hairlines to three research questions: tissue stress, administration time and brain exposure.source-mapped recordsresearch questionGlobal ischemia modelEdema directionAQP4 directionMCAO model2 / 6 / 24 hWindow narrative0.5 h peak<5% at 6 h1.24× brain / plasma AUCTissue stress3 recordsAdministration time3 recordsBrain exposure3 records
04 / Integrated mechanism

One field. Three connected directions.

The source presents Aildenafil through three connected directions: vascular response, neurovascular recovery and neuroprotection.

Conceptual illustration connecting vascular response, neurovascular recovery and neuroprotection01 / Vascular
Select one of three numbered focal points to inspect vascular response, neurovascular recovery and neuroprotection on the same conceptual canvas.
01 / Vascular response

Vascular response

A source-mapped direction of controlled vessel expansion and downstream flow.

View mechanism
02 / Neurovascular recovery

Neurovascular recovery

A research direction spanning microvascular reperfusion and network recovery.

03 / Neuroprotection

Neuroprotection

A source-mapped tissue context for the neural environment under stress.

05 / Evidence

Source-aware by design.

Three mapped contexts answer different questions. Model, observation and source status remain visible.

06 / Company & R&D

Building a quieter way to understand neurovascular science.

Research-oriented. Evidence-aware. International.

R&D, manufacturing and quality are presented through structured, source-mapped facts—not unverified facility imagery or inflated endorsements.

About Lucius

Open, legible and traceable information for professionals and international partners.

International business